Amal SOUIRI

Sanaâ LEMRISS and Saâd EL KABBAJ

PCL3, Gendarmerie Royale, Rabat, Morocco

Abstract

Introduction:

SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Questions regarding the functionality and longevity of humoral immunity remain unanswered. Here we report the assessment of neutralizing antibody response after vaccination with adenovirus-based vector COVID-19 vaccine.

Methods:

Microneutralization (MN) assay using infectious SARS-CoV-2 in comparison with two commercially available kits, a rapid lateral flow immune-chromatographic assay (LFIA) and an Enzyme-linked fluorescence assay (ELFA), were utilized to assess SARS-CoV-2 neutralizing antibody capacity in 150 serum samples of vaccinated laboratory workers,  40 of which were diagnosed positive to COVID-19 during late 2020 and the first quarter of 2021.

Conclusion & Significance:

Neutralizing antibodies were detected in 81 % of healthy individuals and in 90 % of convalescent COVID-19 participants. High anti–SARS-CoV-2 antibody titers were associated with neutralization activity. The strong correlation between microneutralisation and commercially available assays demonstrates their potential for clinical and research use in assessing protection following infection or vaccination.